Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

This study has been terminated.
(Manufacturer stopped drug development)
Novartis Pharmaceuticals
Information provided by (Responsible Party):
David Rizzieri, Duke University Medical Center Identifier:
First received: August 1, 2007
Last updated: May 23, 2013
Last verified: May 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2010
  Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 7, 2012